AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02534415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8% Hyaluronic acid gel
Description: 0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
Study NCT00981461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb
Description: Device application 3 times week, for 26 weeks
Study NCT00981461 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Device
Description: Device application 3 times week, for 26 weeks
Study NCT01008943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells
Description: Urethral injection of autologous muscle-derived cells
Study NCT00936702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00936702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT00936702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01636635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
Study NCT01636635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restriction
Description: Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
Study NCT03371693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Patients consenting to this protocol will undergo their scheduled surgical procedure. After cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm, a single dose of lobaplatin (30 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 60 minutes in the hyperthermic phase (43℃±0.5℃). And HIPEC will be repeated at the 3 and 5 day after the day of CRS plus HIPEC.
Study NCT03371693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRS
Description: cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.
Study NCT03371693 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CRS
Description: cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.
Study NCT03371693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVCT
Description: platinum-based intravenous chemotherapy
Study NCT03371693 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IVCT
Description: platinum-based intravenous chemotherapy
Study NCT03518294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
Study NCT02089919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine
Study NCT02889627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota suspension
Description: The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
Study NCT02287896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROLEDUMAB
Description: See Arm description
Study NCT00617682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNCRM9
Description: 0.5 mL IM at 30-35 wks gestation
Study NCT00617682 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
Study NCT01125215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% capsaicin nanoparticle cream
Description: 0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
Study NCT01125215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
Study NCT01310322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
Study NCT01310322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
Study NCT01310322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
Study NCT01310322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
Study NCT03852797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin solution, 20nM concentration
Study NCT03852797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine in solution, 10-4M to 10-7M
Study NCT03852797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol in solution, 10-4M to 10-7M
Study NCT03852797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate in solution, 10-4M to 10-7M
Study NCT04089540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New intubation method
Study NCT04089540 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional intubation method
Study NCT02699944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Vest Optimization
Description: As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
Study NCT02963493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan flufenamide (Melflufen)
Study NCT02963493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
Study NCT02135575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinning
Description: After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
Study NCT03144180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-cup
Description: This technology is a different way of collecting umbilical cord blood.
Study NCT00660062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 10 mg daily
Study NCT00660062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 20 mg daily dosage
Study NCT00660062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 30 mg daily dosage
Study NCT00660062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline
Description: 100 mg daily dosage
Study NCT03663595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 1
Description: Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
Study NCT03663595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 2
Description: Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
Study NCT01173302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine, manufactured by ChengDa
Description: 1 dose before the antibody is tested
Study NCT01263574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70% ethanol
Description: Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
Study NCT01263574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 70% ethanol
Description: Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
Study NCT03000582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
Study NCT03000582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine nitrate-1
Description: Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
Study NCT03000582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine nitrate-2
Description: Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
Study NCT03000582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (6.5 g dextrose)
Study NCT03746522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: SC injection of setmelanotide
Study NCT03746522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection of placebo
Study NCT04026919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OK EN CASA-ZAINDOO
Description: Intervention based on cognitive- behavioural techniques offered in an online format.
Study NCT02807181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin-gemcitabine
Description: Systemic chemotherapy
Study NCT02807181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-gemcitabine
Description: Systemic chemotherapy
Study NCT02807181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Description: SIR-Spheres microspheres followed by systemic chemotherapy
Study NCT00767676 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HP828-101
Description: Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
Study NCT04404959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fascia iliaca compartment block with ropivacaine
Description: the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of ropivacaine 0.25%)
Study NCT04404959 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fascia iliaca compartment block with placebo
Description: the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of normal saline)
Study NCT04316182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.
Study NCT02346136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Study NCT02346136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Study NCT02117037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Study NCT04426617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Transversus Abdominis Plane Block
Description: The patient will lie in the supine position. The transducer will be placed in the axial plane on the mid-axillary. transversus abdominis muscle will be visualized. A skin wheel using 3 ml of lidocaine 1 % is made 2 to 3 cm medial to the medial aspect of the transducer and the 22 gauge is inserted in-plane pointing laterally. Then Injection of local anaesthetic mixure in the right plane.
Study NCT04426617 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound Guided Transversus Abdominis Plane Block
Description: The patient will lie in the supine position. The transducer will be placed in the axial plane on the mid-axillary. transversus abdominis muscle will be visualized. A skin wheel using 3 ml of lidocaine 1 % is made 2 to 3 cm medial to the medial aspect of the transducer and the 22 gauge is inserted in-plane pointing laterally. Then Injection of local anaesthetic mixure in the right plane.
Study NCT02051465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LumenR Retractor
Description: Polyp removal using LumenR Retractor Modified overtube
Study NCT02051465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removal without overtube
Description: Endoscopic removal of polyp without overtube
Study NCT01140763 — intervention group
Intervention type: DEVICE
Intervention: Sysmex's 5-blade lymph node cutter
Description: A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin \& eosin (H\&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed.
Study NCT02448212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-121
Description: Oral
Study NCT01451346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. Infantis 35624
Description: One sachet daily for 12 weeks
Study NCT01451346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: B. Infantis 35624
Description: One sachet daily for 12 weeks
Study NCT01391728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Lifestyle all your Life
Description: Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves.
Study NCT03608488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D3 50.000 IU/per week, for 8 weeks
Study NCT03608488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Core stability, balance exercises
Study NCT02448212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]TASP0410699
Description: Intravenous radiotracer
Study NCT02448212 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging scanning procedure
Study NCT03608488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Core stability, balance exercises
Study NCT02075320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stationary Digital Chest Tomosynthesis
Description: The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction.
Study NCT01397695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
Study NCT02003625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GCSF
Study NCT02003625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Study NCT02003625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meloxicam
Study NCT02003625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03766100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT-i)
Description: CBT-i aims to alter behaviours that sustain or add to insomnia and correct cognitions that drive these behaviours. The behavioural components of CBT-i are stimulus control (SC) and Sleep Restriction Therapy (SRT). SC works through the extinction of a conditioned arousal that emerges when bed and bedroom have become associated with wakefulness. With SRT time in bed is reduced to build up sleep pressure. When wakefulness is decreased, time in bed is gradually increased until optimal sleep is attained. With the cognitive component, insomnia is treated by identifying and changing unhelpful or inaccurate thinking regarding sleep and distressing emotional responses to insomnia. The last component of CBT-i aims to reduce hyperarousal with relaxation techniques, scheduled worry time, creating a time to unwind, and employing cognitive therapy strategies.
Study NCT00684424 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Observational Only
Study NCT03296306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment duration of cisplatin based chemotherapy
Description: * GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~* GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~* MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~* HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks
Study NCT03296306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment duration of cisplatin based chemotherapy
Description: * GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~* GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~* MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~* HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks
Study NCT01072851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia Education
Description: A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
Study NCT01072851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Print Media
Description: Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
Study NCT01072851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual and customary waiting room process
Description: No specialized educational intervention to promote colorectal cancer screening or to explain the process
Study NCT04059848 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: tDCS(Intelect Mobile Stimulation and Combination, DJO, France)